Azitra, Inc. Share Price & Technical Analysis
AZTR · $0.21 (+5.00%)
Healthcare / Biotechnology
$0.21
+5.00%
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer pati…
Price chart
Seasonality
May has 0 positive and 3 negative years (last 4 years shown)
-33% return in May, -12% avg return in past 3 year May month.
-67% return in 2026, -188% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -33% | 0% | 0% | 0% | -33% | – | – | – | – | – | – | – | -67% |
| 25 | -47% | 41% | -17% | 16% | -10% | -6% | -29% | -8% | -30% | -29% | -20% | -25% | -163% |
| 24 | 19% | -80% | -17% | 5% | -15% | -51% | -72% | -20% | -16% | -11% | 6% | -18% | -270% |
| 23 | – | – | – | – | – | -15% | 7% | -49% | -28% | 0% | -32% | -16% | -132% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$3.68M
P/E ratio
—
52W high
$2.40
52W low
$0.10
Volume
69,971
Beta
-1.39
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Azitra, Inc. share price today?
- Azitra, Inc. (AZTR) last traded around $0.21 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does AZTR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for AZTR. Download the app for real-time alerts.
- How can I analyze Azitra, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.